Advertisement
CBOE vs CME
Which Stock Would AI Choose? Cboe Global Markets (CBOE) vs. CME Group (CME) Stock Comparison
Key Takeaways
- Both CBOE and CME are exchange operators that posted record financial results recently, but they derive growth from different product mixes and customer bases.
- CBOE is skewing toward options, index products, and data under a new CEO, while divesting smaller international businesses to sharpen focus.
- CME dominates futures and clearing, and is investing in 24/7 crypto trading, event contracts, and a new securities clearinghouse as growth drivers.
- Analyst sentiment has diverged somewhat: CBOE received a recent upgrade, while CME carries a more mixed rating profile despite record volumes.
- Relative performance favors different profiles — CBOE leans on higher-margin index and data revenue, while CME offers greater scale and diversification across interest rates, energy, metals, and crypto.
- For ongoing coverage, explore CBOE Major News and CBOE Today's Price Move, plus CME Major News and CME Today's Price Move.
- To see how AI approaches this and other comparisons in real time, browse the Trending AI Robots.
Introduction
Exchange operators are often viewed as durable, cash-generative businesses that benefit from trading activity regardless of market direction. CBOE and CME are two of the most prominent names in this space, yet they occupy different corners of the derivatives and securities ecosystem. This stock comparison is relevant for investors and traders evaluating how market positioning, product innovation, and relative performance differ between a diversified futures and clearing franchise and an options-and-index specialist. Understanding these contrasts can help readers assess which business model aligns with their own view of market volatility, interest rates, and long-term trading-volume trends.
CBOE Overview and Recent Performance
Cboe Global Markets, Inc. (CBOE) operates options, futures, and securities exchanges, and is best known for its proprietary index options, including S&P 500 Index (SPX) options and VIX volatility products. In recent weeks, the company has reported record quarterly revenue, driven by double-digit growth in options revenue and strength in its derivatives and data segments. Adjusted earnings per share rose sharply year over year, reflecting both higher volumes and improved operating leverage.
Sentiment has been shaped by a strategic realignment under new leadership. The company has announced plans to divest smaller businesses in Australia and Canada, wind down parts of its European derivatives platform, and discontinue corporate listings efforts — moves aimed at concentrating resources on its core index and options franchise. Barclays upgraded CBOE to Overweight in the recent period, citing healthy index-options growth and the sharper strategic focus. The main watchpoints include concentration risk around its flagship index products and ongoing competitive and fee pressures across exchanges.
CME Overview and Recent Performance
CME Group Inc. (CME) is the world's largest futures exchange operator, offering trading and clearing across interest rates, equities, energy, agriculture, metals, and foreign exchange. In recent weeks, the company reported its fourth consecutive year of record annual revenue and adjusted earnings, with quarterly revenue up year over year on higher clearing and transaction fees. Average daily volume (ADV) reached record levels, supported by strength in equities, metals, and cryptocurrency products.
Sentiment has been influenced by growth initiatives rather than retrenchment. Management highlighted expansion into 24/7 crypto trading, a new securities clearinghouse, and event contracts, which have drawn meaningful early volume. Crypto-related daily volumes rose sharply, and market data revenue reached a record. At the same time, CME signaled higher 2026 expenses tied to these investments, a factor analysts weigh against its otherwise stable, high-margin business. The rating profile has been mixed, with one firm upgrading to Buy while others hold at neutral positions.
Trending AI Robots
Tickeron maintains a large library of AI trading bots covering thousands of different tickers, but not all of them earn a place in the curated Trending AI Robots section. Only the bots best suited to current market conditions are featured there. These bots vary widely in trading style, strategy, timeframe, performance history, and the set of tickers they follow, so the selection is designed to surface the models currently demonstrating the strongest alignment with prevailing trends. Readers interested in seeing which automated strategies are being highlighted for the present environment — including those that may be tracking exchange operators like CBOE and CME — can explore the Trending AI Robots page to review the latest featured bots and their statistics.
Head-to-Head Comparison
The clearest contrast between these two stocks is business mix. CME is the larger, more diversified franchise, with revenue spread across a broad futures and clearing complex and a market capitalization exceeding $100 billion. CBOE is smaller and more concentrated, with outsized dependence on proprietary index options and data, which carry attractive margins but expose it to product-specific competition.
Growth drivers also differ. CBOE is pursuing growth through focus — expanding near-24-hour trading for index options and leaning into high-margin data and index revenue while exiting sub-scale businesses. CME is pursuing growth through expansion, investing in crypto, event contracts, and clearing infrastructure. Risk factors vary accordingly: CBOE faces concentration and execution risk from its restructuring, while CME faces expense growth and integration risk from new initiatives. On momentum, both delivered record results, but CBOE has seen comparatively stronger near-term analyst momentum, while CME has posted steadier, scale-driven performance.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalysts, and relative positioning, Tickeron's AI would likely assign a modest edge to CBOE in the current environment. The combination of record earnings, a recent analyst upgrade, and a strategy that concentrates capital on higher-margin index and options products points to a clearer near-term catalyst set than CME's longer-horizon investment programs. However, CME offers greater stability, diversification, and scale, which could favor it under more risk-averse or longer-timeframe conditions. The assessment is probabilistic rather than definitive, and the relative advantage may shift as new volume and earnings data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CBOE is a Buy and CME is a StrongBuy.
CBOE in upward trend: price rose above 50-day moving average on October 08, 2026
CBOE moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for CBOE crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
The 50-day moving average for CBOE moved above the 200-day moving average on October 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBOE advanced for three days, in 203 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 172 of 272 cases where CBOE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBOE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
CBOE broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. CBOE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock better than average.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.558) is normal, around the industry mean (4.143). P/E Ratio (27.449) is within average values for comparable stocks, (19.659). Projected Growth (PEG Ratio) (2.241) is also within normal values, averaging (1.780). Dividend Yield (0.010) settles around the average of (0.017) among similar stocks. P/S Ratio (5.615) is also within normal values, averaging (7.166).
CME in upward trend: 10-day moving average broke above 50-day moving average on October 14, 2026
The 10-day moving average for CME crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on CME as a result. In 56 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on November 11, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 172 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 137 of 261 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
CME broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.147) is normal, around the industry mean (4.143). P/E Ratio (25.814) is within average values for comparable stocks, (19.659). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). Dividend Yield (0.017) settles around the average of (0.017) among similar stocks. CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).
CBOE | CME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 21 | 32 | |
SMR RATING 1..100 | 37 | 54 | |
PRICE GROWTH RATING 1..100 | 8 | 23 | |
P/E GROWTH RATING 1..100 | 46 | 50 | |
SEASONALITY SCORE 1..100 | 47 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CBOE's Valuation (90) in the Investment Banks Or Brokers industry is in the same range as CME (94). This means that CBOE’s stock grew similarly to CME’s over the last 12 months.
CBOE's Profit vs Risk Rating (21) in the Investment Banks Or Brokers industry is in the same range as CME (32). This means that CBOE’s stock grew similarly to CME’s over the last 12 months.
CBOE's SMR Rating (37) in the Investment Banks Or Brokers industry is in the same range as CME (54). This means that CBOE’s stock grew similarly to CME’s over the last 12 months.
CBOE's Price Growth Rating (8) in the Investment Banks Or Brokers industry is in the same range as CME (23). This means that CBOE’s stock grew similarly to CME’s over the last 12 months.
CBOE's P/E Growth Rating (46) in the Investment Banks Or Brokers industry is in the same range as CME (50). This means that CBOE’s stock grew similarly to CME’s over the last 12 months.
| CBOE | CME | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 44% | 1 day ago 50% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 54% |
| Momentum ODDS (%) | N/A | 1 day ago 52% |
| MACD ODDS (%) | N/A | 1 day ago 53% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 52% |
| TrendMonth ODDS (%) | 1 day ago 61% | 1 day ago 53% |
| Advances ODDS (%) | 3 days ago 63% | 3 days ago 50% |
| Declines ODDS (%) | 16 days ago 42% | 5 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 57% | 1 day ago 50% |
| Aroon ODDS (%) | 1 day ago 63% | 1 day ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CBOE’s FA Score shows that 2 FA rating(s) are green while CME’s FA Score has 2 green FA rating(s).
- CBOE’s FA Score: 2 green, 3 red.
- CME’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CBOE’s TA Score shows that 5 TA indicator(s) are bullish while CME’s TA Score has 6 bullish TA indicator(s).
- CBOE’s TA Score: 5 bullish, 4 bearish.
- CME’s TA Score: 6 bullish, 4 bearish.
Price Growth
CBOE (@Financial Publishing/Services) experienced а +4.48% price change this week, while CME (@Financial Publishing/Services) price change was +2.69% for the same time period.
The average weekly price growth across all stocks in the @Financial Publishing/Services industry was -0.60%. For the same industry, the average monthly price growth was +7.55%, and the average quarterly price growth was +14.30%.
Reported Earning Dates
CBOE is expected to report earnings on Jan 29, 2027.
CME is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Financial Publishing/Services (-0.60% weekly)The financial publishing /services sector includes companies that provide informational products and services that are of value to investors, financial/analytics professionals and other interested readers. The products include real-time stock quotes, financial news and analyses. Think S&P Global, Inc., Moody`s Corporation, Thomson-Reuters Corp and IHS Markit Ltd. Information is critical in making financial or investment decisions, and what makes this industry’s output relevant at all times, across various economic conditions.
Advertisement
CBOE and
Correlation & Price change
A.I.dvisor indicates that over the last year, CBOE has been loosely correlated with CME. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CBOE jumps, then CME could also see price increases.
| Ticker / NAME | Correlation To CBOE | 1D Price Change % | ||
|---|---|---|---|---|
| CBOE | 100% | -0.08% | ||
| CME - CBOE | 60% Loosely correlated | -0.12% | ||
| ICE - CBOE | 30% Poorly correlated | -1.51% | ||
| MKTX - CBOE | 29% Poorly correlated | -0.09% | ||
| TW - CBOE | 29% Poorly correlated | +0.80% | ||
| ARBK - CBOE | 22% Poorly correlated | -17.52% | ||
More | ||||
CME and
Correlation & Price change
A.I.dvisor indicates that over the last year, CME has been loosely correlated with ICE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CME jumps, then ICE could also see price increases.
| Ticker / NAME | Correlation To CME | 1D Price Change % | ||
|---|---|---|---|---|
| CME | 100% | -0.12% | ||
| ICE - CME | 51% Loosely correlated | -1.51% | ||
| TW - CME | 45% Loosely correlated | +0.80% | ||
| NDAQ - CME | 36% Loosely correlated | -0.94% | ||
| MKTX - CME | 35% Loosely correlated | -0.09% | ||
| MSCI - CME | 30% Poorly correlated | -1.51% | ||
More | ||||